Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
Biofrontera AG announced the issuance of up to 2,638,150 qualified subordinated mandatory convertible bonds with a 1.00% interest rate. The bonds were priced at EUR 3.00 each, raising gross proceeds of EUR 7.9 million. The offering was significantly oversubscribed, indicating strong investor interest and confidence in Biofrontera's strategy. The bonds will be used to attract new investors and support existing shareholders. The private placement was conducted exclusively among investors in the DACH region, with Quirin Privatbank AG acting as the sole bookrunner.
- Oversubscribed issuance of convertible bonds, indicating strong market demand.
- Gross proceeds of EUR 7.9 million raised, enhancing financial stability.
- None.
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150
"The capital market responded with great interest to the issuance of our convertible bond. We were able to attract new investors to Biofrontera during these challenging times. This and particularly the demand expressed by our existing shareholders underline the confidence of the capital market in Biofrontera's strategy. We would like to express our sincere thanks for this," commented Hermann Lübbert, CEO of Biofrontera AG, on the successful completion of the capital measure.
Overall, the capital measure was significantly oversubscribed. The allocation was made in accordance with the criteria published in the subscription offer. Investors from the DACH region subscribed to the Bonds in the private placement, in which Quirin Privatbank AG acted as sole bookrunner.
-END-
For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer | +49 (0) 214 87 63 2 0 ir@biofrontera.com |
R UK: Seton Services Toni Vallen | +44 (0) 207 229 0805 |
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
FAQ
What was the purpose of Biofrontera AG's recent bond issuance?
What is the interest rate of the convertible bonds issued by Biofrontera AG?
When was the subscription period for Biofrontera AG's bonds?
Who acted as the bookrunner for Biofrontera AG's bond offering?